Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Stephen P. Ducray"'
Autor:
Perla Pucci, Liam C. Lee, Miaojun Han, Jamie D. Matthews, Leila Jahangiri, Michaela Schlederer, Eleanor Manners, Annabel Sorby-Adams, Joshua Kaggie, Ricky M. Trigg, Christopher Steel, Lucy Hare, Emily R. James, Nina Prokoph, Stephen P. Ducray, Olaf Merkel, Firkret Rifatbegovic, Ji Luo, Sabine Taschner-Mandl, Lukas Kenner, G. A. Amos Burke, Suzanne D. Turner
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-19 (2024)
Abstract Targeting Anaplastic lymphoma kinase (ALK) is a promising therapeutic strategy for aberrant ALK-expressing malignancies including neuroblastoma, but resistance to ALK tyrosine kinase inhibitors (ALK TKI) is a distinct possibility necessitati
Externí odkaz:
https://doaj.org/article/12cef060f54047bf95b2dad4e211f0d7
Autor:
Hugo Larose, Nina Prokoph, Jamie D. Matthews, Michaela Schlederer, Sandra Högler, Ali F. Alsulami, Stephen P. Ducray, Edem Nuglozeh, Feroze M.S. Fazaludeen, Ahmed Elmouna, Monica Ceccon, Luca Mologni, Carlo Gambacorti-Passerini, Gerald Hoefler, Cosimo Lobello, Sarka Pospisilova, Andrea Janikova, Wilhelm Woessmann, Christine Damm-Welk, Martin Zimmermann, Alina Federova, Andrea Malone, Owen Smith, Mariusz Wasik, Giorgio Inghirami, Laurence Lamant, Tom L. Blundell, Wolfram Klapper, Olaf Merkel, G.A. Amos Burke, Shahid Mian, Ibraheem Ashankyty, Lukas Kenner, Suzanne D. Turner
Publikováno v:
Haematologica, Vol 106, Iss 6 (2020)
Patients diagnosed with Anaplastic Large Cell Lymphoma (ALCL) are still treated with toxic multi-agent chemotherapy and as many as 25-50% of patients relapse. To understand disease pathology and to uncover novel targets for therapy, Whole-Exome Seque
Externí odkaz:
https://doaj.org/article/ac9c68b0d9e342ba919d333429ab5aaa
Autor:
Gavin D. Garland, Stephen P. Ducray, Leila Jahangiri, Perla Pucci, G. A. Amos Burke, Jack Monahan, Raymond Lai, Olaf Merkel, Ana-Iris Schiefer, Lukas Kenner, Andrew J. Bannister, Suzanne D. Turner
Publikováno v:
Cancers, Vol 14, Iss 1, p 151 (2021)
Anaplastic large-cell lymphoma (ALCL) is a T-cell malignancy driven in many cases by the product of a chromosomal translocation, nucleophosmin–anaplastic lymphoma kinase (NPM-ALK). NPM-ALK activates a plethora of pathways that drive the hallmarks o
Externí odkaz:
https://doaj.org/article/608ab39e7b67415ea99ca3aae65cf0eb
Publikováno v:
Cancers, Vol 11, Iss 8, p 1074 (2019)
Anaplastic lymphoma kinase (ALK) is a tyrosine kinase involved in neuronal and gut development. Initially discovered in T cell lymphoma, ALK is frequently affected in diverse cancers by oncogenic translocations. These translocations involve different
Externí odkaz:
https://doaj.org/article/9585af1acdc648419ef1a3d8058bd89b
Autor:
Gerald Hoefler, Jamie D. Matthews, Mariusz A. Wasik, Cosimo Lobello, Šárka Pospíšilová, Feroze Fazaludeen, Ahmed Elmouna, Monica Ceccon, Edem Nuglozeh, Martin Zimmermann, Michaela Schlederer, Hugo Larose, Christine Damm-Welk, Wilhelm Woessmann, Lukas Kenner, Giorgio Inghirami, Wolfram Klapper, Ibraheem Ashankyty, Olaf Merkel, Tom L. Blundell, Nina Prokoph, Shahid Mian, Luca Mologni, Laurence Lamant, Andrea Janíková, Andrea Malone, Alina Federova, G. A. Amos Burke, Suzanne D. Turner, Owen P. Smith, Carlo Gambacorti-Passerini, Sandra Högler, Ali F. Alsulami, Stephen P. Ducray
Publikováno v:
Haematologica
Patients diagnosed with anaplastic large cell lymphoma (ALCL) are still treated with toxic multi-agent chemotherapy and as many as 25-50% of patients relapse. To understand disease pathology and to uncover novel targets for therapy, we performed whol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0bdffe2951211b6f92b06fdfe98cb310
http://hdl.handle.net/10281/336945
http://hdl.handle.net/10281/336945
Autor:
Geeta G. Sharma, Sorcha Forde, Hélène Pacquement, Ivonne A. Montes-Mojarro, Ralf Jauch, Wolfram Klapper, Cosimo Lobello, Liam C. Lee, Luca Mologni, Anne Lambilliotte, Suzanne D. Turner, Laurence Brugières, Roberto Chiarle, Stephen P. Ducray, Jamie D. Matthews, Birgit Geoerger, Shahid Pervez, Carlo Gambacorti-Passerini, Lukas Kenner, Šárka Pospíšilová, Klaas Bahnsen, Shi-Lu Luan, Nina Prokoph, Andrea Janíková, G. A. Amos Burke, Olaf Merkel, Huan-Chang Liang, Elif Karaca-Atabay, Hugo Larose, Wilhelm Woessmann, Qi Wang, Andishe Attarbaschi, Jack M. Monahan, Vikas Malik, Judith Landman-Parker, Isaia Barbieri, Gilles Vassal, Gudrun Schleiermacher, Nicola A. Probst
Anaplastic large cell lymphoma (ALCL) is a T-cell malignancy predominantly driven by a hyperactive anaplastic lymphoma kinase (ALK) fusion protein. ALK inhibitors, such as crizotinib, provide alternatives to standard chemotherapy with reduced toxicit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ae853e045a135b7e317c7f6be0735d41
https://www.repository.cam.ac.uk/handle/1810/305799
https://www.repository.cam.ac.uk/handle/1810/305799
Autor:
Olaf Merkel, Ricky M Trigg, Gerda Egger, Stephen P. Ducray, Raymond Lai, Lukas Kenner, Andrew J. Bannister, Suzanne D. Turner
Publikováno v:
Blood. 134:1483-1483
Introduction Through conserved signalling pathways, Anaplastic Lymphoma Kinase (ALK) is well-described in driving haematological malignancies including Anaplastic Large Cell Lymphoma (ALCL) and Diffuse Large B-Cell Lymphoma (DLBCL) and as such presen
Publikováno v:
Cancers, Vol 11, Iss 8, p 1074 (2019)
Cancers
Cancers
Anaplastic lymphoma kinase (ALK) is a tyrosine kinase involved in neuronal and gut development. Initially discovered in T cell lymphoma, ALK is frequently affected in diverse cancers by oncogenic translocations. These translocations involve different